MacroGenics (MGNX) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics (MGNX) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 106.4% versus a loss of 4.1%. MacroGenics is the larger company by market cap ($226.1 million vs $218.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | TRDA |
|---|---|---|
| Share price | $3.55 | $5.61 |
| Market cap | $226.14M | $218.43M |
| 1-day change | -2.47% | +3.51% |
| YTD return | +120.50% | -45.43% |
| 1-year return | +106.40% | -4.10% |
| 5-year return | -82.02% | — |
| EPS (TTM) | $-1.70 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $16.45 |
| 52-week low | $1.29 | $5.15 |
| Distance from 52-week high | -30.12% | -65.90% |
| Analyst consensus | buy | none |
| Avg. price target upside | +125.35% | +238.68% |
| Average volume | 621.73K | 359.01K |
| Shares outstanding | 63.70M | 38.94M |
| Employees | 293 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed TRDA by 110.5 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
MGNX vs TRDA FAQ
Which is bigger, MacroGenics or Entrada Therapeutics?
MacroGenics (MGNX) is larger, with a market capitalization of $226.14M compared with $218.43M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, MGNX or TRDA?
MGNX returned +106.40% over the past 12 months, compared with -4.10% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.